Thursday, September 29th (9h30-11h00)
Room D

Regenerative Medicine has raised expectations for revolutionizing the treatment of many serious diseases for which current therapies are inadequate or simply inexistent. However, its incorporation into clinical practice has progressed much more slowly than predicted. In this session, we’ll review some recent successful examples and approaches in Regenerative Medicine. We will also focus on and discuss potential pitfalls and strategies to mitigate them from the perspective of biotech/pharma companies. The influence of the different regulatory landscapes and the role of stakeholders will also be addressed.

Sponsored by:


Andrés G. Fernández: Director, Ferrer Advanced Biotherapeutics, FERRER (Spain)


Eduardo Anitua: President & Scientific Director, BTI BIOTECHNOLOGY INSTITUTE (Spain). "From the idea to the market. New challenges and opportunities in Regenerative Medicine"
Michael H. May: President & CEO, Centre for Commercialization of Regenerative Medicine-CCRM (Canada)
Julio Font: CEO, HISTOCELL (Spain). "Histocell: new generation of mesenchymal stem cells for human health".
Miguel Mulet: Director Strategy, TIGENIX (Spain). "Regenerative Cell Therapy, Why now".